<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636853</url>
  </required_header>
  <id_info>
    <org_study_id>3417</org_study_id>
    <nct_id>NCT04636853</nct_id>
  </id_info>
  <brief_title>CB-PRP in Retinitis Pigmentosa</brief_title>
  <acronym>SiCord</acronym>
  <official_title>Cord Blood Platelet-rich Plasma (CB-PRP) in Retinitis Pigmentosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will provides the enrollment of patients with genetic retinal dystrophies with&#xD;
      primary rod impairment.&#xD;
&#xD;
      A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be&#xD;
      performed only in one eye, the other eye will be considered as a control group.&#xD;
&#xD;
      A complete morpho-functional ophthalmological evaluation will be performed in all patient at&#xD;
      each control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients underwent genetic evaluation and they reported different types of mutations that&#xD;
      induce anatomic-functional impairment of the rods.&#xD;
&#xD;
      After selecting the patients to be enrolled, the study will proceed with the vitrectomy&#xD;
      surgery and a subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)&#xD;
      provided by the Umbilical Cord Bank according to the procedures provided for by the current&#xD;
      legislation on blood components for non-transfusion use.&#xD;
&#xD;
      A complete ophthalmological examination will be performed at 1, 3, 6 and 12 months. They will&#xD;
      include:&#xD;
&#xD;
        -  Anterior segment biomicroscopy&#xD;
&#xD;
        -  direct and indirect ophthalmoscopy&#xD;
&#xD;
        -  ETDRS visual acuity assessment&#xD;
&#xD;
        -  intraocular pressure measurement&#xD;
&#xD;
        -  optical coherence tomography (OCT)&#xD;
&#xD;
        -  OCT Angiography (OCTA)&#xD;
&#xD;
      The following assessments will be performed at baseline and at 6 and 12 months.&#xD;
&#xD;
        -  Microperimetry&#xD;
&#xD;
        -  ERG (elettroretinogramma) -&#xD;
&#xD;
        -  PEV (potenziali evocati visivi)&#xD;
&#xD;
        -  contrast sensitivity (MARS tables)&#xD;
&#xD;
        -  Goldmann perimetry&#xD;
&#xD;
      The some morpho-functional data will also be collected in the contralateral eye and used as&#xD;
      control group.&#xD;
&#xD;
      To ensure the best safety for the patient, the first 5 eyes will be separated by a minimum of&#xD;
      20 days in order to observe the post-surgical evolution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) morphological changes</measure>
    <time_frame>3 years</time_frame>
    <description>Differences in structural optical coherence tomography (OCT) and OCT Angiography (OCTA) images</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Affected Individual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)</intervention_name>
    <description>A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.&#xD;
A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control.</description>
    <arm_group_label>Affected Individual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Retinal dystrophies with compromised rods&#xD;
&#xD;
          -  Visual Field (Manual Goldmann) V / 4e &lt; 30 Â°&#xD;
&#xD;
          -  Best corrected visual acuity &gt; Light perception&#xD;
&#xD;
          -  Known genotype&#xD;
&#xD;
          -  No or minimal opacity of ocular media&#xD;
&#xD;
          -  No concomitant ocular (eg glaucoma, amblyopia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previous inflammatory / infectious events involving the eyes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Savastano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario A. Gemelli, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfonso Savastano, MD</last_name>
    <phone>+390630154928</phone>
    <email>alfonso.savastano@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfonso Savastano</last_name>
    <phone>+390630154928</phone>
    <email>alfonso.savastano@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfonso Savastano</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Savastano</last_name>
      <phone>+390630154928</phone>
      <email>alfonso.savastano@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Valentini CG, Nuzzolo ER, Bianchi M, Orlando N, Iachininoto MG, Pinci P, Teofili L. Cord Blood Platelet Lysate: In Vitro Evaluation to Support the Use in Regenerative Medicine. Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019021. doi: 10.4084/MJHID.2019.021. eCollection 2019.</citation>
    <PMID>30858959</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord blood plateled-rich plasma</keyword>
  <keyword>Retinitis pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

